Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

Autor: Wu SY; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Damron EP; The University of Texas Health Science Center at Houston, Houston, TX, USA., Xu J; Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fang PQ; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dai J; Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nair R; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Malpica Castillo LE; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fayad LE; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Torres-Cabala CA; Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Medeiros LJ; Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vega F; Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Miranda RN; Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duvic M; Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pinnix CC; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dabaja BS; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Iyer SP; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huen AO; Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gunther JR; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: International journal of dermatology [Int J Dermatol] 2024 Jul 02. Date of Electronic Publication: 2024 Jul 02.

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma.

Autor: Wu SY; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Fang PQ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Wang EB; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Ahmed S; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Duvic M; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas., Jain P; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Castillo LEM; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Nair R; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Steiner RE; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Strati P; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Huen AO; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas., Iyer SP; Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Pinnix CC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Dabaja BS; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Gunther JR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Advances in radiation oncology [Adv Radiat Oncol] 2023 Jun 02; Vol. 8 (6), pp. 101279. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.

Autor: Patel AB; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas., Farooq S; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas., Welborn M; Department of Dermatology, University of Florida, Gainesville, Florida., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chon SY; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Glitza Oliva IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huen AO; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li SQ; Baylor College of Medicine, Houston, Texas., Nelson KC; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas., Pacha O; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rapini RP; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; McGovern Medical School, The University of Texas Health Science Center, Houston, Texas., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., McQuade J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Haydu LE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer [Cancer] 2022 Mar 01; Vol. 128 (5), pp. 975-983. Date of Electronic Publication: 2021 Nov 01.

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.

Autor: Musiek ACM; Division of Dermatology, Washington University School of Medicine, 4901 Forest Park, Suite 502, Saint Louis, MO, 63108, USA. amusiek@wustl.edu., Rieger KE; Stanford University, Stanford, CA, USA., Bagot M; Hôpital Saint Louis, APHP, Inserm U976, Université de Paris, Paris, France., Choi JN; Northwestern University, Evanston, IL, USA., Fisher DC; Dana-Farber Cancer Institute, Boston, MA, USA., Guitart J; Northwestern University, Evanston, IL, USA., Haun PL; University of Pennsylvania, Philadelphia, PA, USA., Horwitz SM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Huen AO; MD Anderson Cancer Center, Houston, TX, USA., Kwong BY; Stanford University, Stanford, CA, USA., Lacouture ME; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Noor SJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rook AH; University of Pennsylvania, Philadelphia, PA, USA., Seminario-Vidal L; University of South Florida and H. Lee Moffitt Cancer Center, Tampa, FL, USA., Vermeer MH; Leiden University, Leiden, The Netherlands., Kim YH; Stanford University, Stanford, CA, USA.

Publikováno v: Dermatology and therapy [Dermatol Ther (Heidelb)] 2022 Jan; Vol. 12 (1), pp. 29-40. Date of Electronic Publication: 2021 Nov 23.

Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse.

Autor: Nguyen CN; School of Medicine, Baylor College of Medicine, Houston, Texas., Iyer SP; Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Miranda RN; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Torres-Cabala CA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Curry JL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fang P; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Thomas VD; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huen AO; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: JAAD case reports [JAAD Case Rep] 2021 Sep 20; Vol. 17, pp. 34-37. Date of Electronic Publication: 2021 Sep 20 (Print Publication: 2021).